Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy

Sakellariou, G; Vounotrypidis, Periklis; Berberidis, Charalampos

doi:10.1007/s10067-006-0422-z

Cited by 21 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asymptomatic persistent or intermittent microscopic hematuria and proteinuria are usually the first signs. 7,8 As in our case, occurrence of IgAN under infliximab was reported previously. Hypertension, high glomerular histopathological scores, persistent hematuria, proteinuria > 1 g/d, and impaired renal function favor a poorer prognosis.…”

supporting

confidence: 78%

“…Hypertension, high glomerular histopathological scores, persistent hematuria, proteinuria > 1 g/d, and impaired renal function favor a poorer prognosis. 8 Despite initial improvement of psoriasis and proteinuria with ustekinumab, we cannot assess whether ustekinumab had any effect on the course of nephropathy in the long term. Polyclonal subclass IgA1 deposit complexes activate mesangial cells after fixation to the mesangium inducing proinflammatory mediators (interleukins 1, 6, and 8, inducible protein-10, and macrophage inflammatory protein) and growth factor (tumor necrosis factor [TNF]a, transforming growth factor b) production, able to induce mesangial cell proliferation and extracellular matrix increase.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis‐associated IgA nephropathy under infliximab therapy

et al. 2014

View full text Add to dashboard Cite

supporting

confidence: 78%

mentioning

confidence: 99%

Psoriasis‐associated IgA nephropathy under infliximab therapy

et al. 2014

View full text Add to dashboard Cite

“…3,4 The types of renal impairment reported are as follows: renal amyloidosis, nephropathy related to non-steroidal anti-infl ammatory drugs (NSAIDs), extracapillary GN due to treatment with anti-tumor necrosis factor (anti-TNF), membranous GN, and mesangial IgA GN. [3][4][5][6][7][8][9][10][11][12][13][14][15] There is a hypothesis that IgA nephropathy and ankylosing spondylitis might share etiopathogenic mechanisms. 16 GN comprise a large variety of immune mediated changes that cause infl ammation mainly in the renal glomerulus.…”

Section: Introductionmentioning

confidence: 99%

Nefropatia por IgA em portadores de espondiloartrites acompanhados no Serviço de Reumatologia do Hospital das Clínicas da UFMG

Azevedo¹,

Ferreira²,

Carvalho³

2011

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Objective: To determine the frequency of glomerulonephritis in patients with spondyloarthritis followed-up at a Brazilian Rheumatology Service, and to evaluate the clinical variables associated. Patients and methods: Patients were assessed for sociodemographic characteristics, type of spondyloarthritis, time since diagnosis and disease activity, non-steroidal anti-infl ammatory drug use, HLA-B27 positivity, creatinine and urea serum levels, major comorbidities, hematuria and proteinuria. Patients with hematuria were subsequently assessed for the presence of dysmorphic red blood cells in urine, and those with proteinuria underwent 24-hour urine protein measurement. Renal biopsy was performed in patients with glomerular hematuria and/or proteinuria over 3.5 g/24-hour. Results: Seventy-six patients were assessed. Microscopic hematuria was the most frequently found abnormality in urinalysis (44.7%), usually intermittent and in spot urine samples during patients' follow-up. In eight patients (10.5%), glomerular hematuria was suspected. Renal biopsy was performed in fi ve of them, showing IgA nephropathy in four (5.3%) and thin membrane disease in one patient. Conclusions: A high frequency of urinalysis alterations was observed in that subgroup of patients, as well as a high prevalence of IgA nephropathy. Although further studies on this subject are needed to better clarify these results, periodic urinalysis of patients with spondyloarthritis should be recommended.

show abstract

“…The patient was treated with an elemental diet combined with oral prednisolone, followed by maintenance therapy with salazosulfapyridine, resulting in clinical improvement of both CD and proteinuria [11]. Sakellariou et al describe two cases of patients with psoriatic arthritis and secondary IgA nephropathy who were treated with infliximab [12]. In both cases, proteinuria improved promptly after infusion of infliximab.…”

Section: Discussionmentioning

confidence: 97%

Infliximab treatment for Crohn’s disease in a patient with IgA nephropathy

Ueno

Tanaka

Onitake

et al. 2009

Clin J Gastroenterol

View full text Add to dashboard Cite

We describe herein a case of IgA nephropathy in a 34-year-old woman with Crohn's disease (CD) treated with infliximab. CD first appeared at the age of 15 years. An elemental diet was started for remission maintenance. Ten years later, the patient suffered from a recto-vaginal fistula and subtotal colectomy with stoma formation was performed. At the age of 33 years, the patient was investigated for painless macroscopic hematuria and proteinuria. Renal biopsy revealed IgA nephropathy. Mizoribine was started but proteinuria persisted. Due to diarrhea she was admitted to our hospital, and scheduled maintenance therapy with infliximab was initiated. After the first infliximab infusion, the patient presented significant clinical improvement in both diarrhea and proteinuria with concomitant decrease of C-reactive protein to normal levels and proteinuria ~1 g/day. This represents the first report of infliximab treatment in a patient with IgA nephropathy associated with CD and clarifies the importance of tumor necrosis factor-alpha (TNFα) in immunity to renal disease. Further studies are needed to draw firm conclusions for the safety of infliximab in patients with IgA nephropathy.

show abstract

Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy

Cited by 21 publications

References 11 publications

Psoriasis‐associated IgA nephropathy under infliximab therapy

Psoriasis‐associated IgA nephropathy under infliximab therapy

Nefropatia por IgA em portadores de espondiloartrites acompanhados no Serviço de Reumatologia do Hospital das Clínicas da UFMG

Infliximab treatment for Crohn’s disease in a patient with IgA nephropathy

Contact Info

Product

Resources

About